EUVIMEDSkopri EUVIMED
Open access

Discovery of GBA-16-24 as a highly potent, selective ATR inhibitor for the treatment of FLT3-mutated acute myeloid leukemia

Ping Li, Haiyan Ren, Xinyan Lan, Junfei Li, Zhi Liu, Huashuo Liu, Zhijie Zheng, Tianyan Zeng, Peili Wang, Mingyang Sun, Lei Xu, Yanyan Zhang iD and 4 more

RSC Medicinal Chemistry · 2026 · 17 (4) · 2081-2095

DOI: 10.1039/d5md01005e ↗

At a glance

Journal article in RSC Medicinal Chemistry, 2026. Written by Ping Li and 15 co-authors. Institution: State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, School of Pharmaceutical Sciences, Guizho…. Cited 1 times so far (Crossref); 56 references. The full text is freely available in PubMed Central. Funded by: National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province, Taishan Scholar Project of Shandong Province.

AstrattDettalji biblijografiċiCiteRelated studies

Abstract (original language)

A novel and selective ATR inhibitor, GBA-16-24 , was developed. It exhibits potent synthetic lethality in FLT3-mutated AML and synergizes with clinical FLT3 inhibitors, proposing a promising combination therapy.

Authors and institutions

  • State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, School of Pharmaceutical Sciences, Guizhou Medical University Guiyang 550025 China wangmingliang@simm.ac.cn.
  • Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences Zhongshan 528400 China ybzhou@simm.ac.cn jli@simm.ac.cn jiangkailong@zidd.ac.cn.
  • Zhuhai Campus of Zunyi Medical University Zhuhai 519000 China.
  • School of Pharmaceutical Sciences, Southern Medical University Guangzhou 510515 China.
  • School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences Hangzhou 310024 China.
  • Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery Yantai 264117 China.

ORCID profiles: Yanyan Zhang, Mingliang Wang, Kailong Jiang

Funding

  • National Natural Science Foundation of China
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Taishan Scholar Project of Shandong Province

Cite

APA

Li, P., Ren, H., Lan, X., Li, J., Liu, Z., Liu, H., Zheng, Z., Zeng, T., Wang, P., Sun, M., Xu, L., Zhang, Y., Zhou, Y., Li, J., Wang, M., & Jiang, K. (2026). Discovery of GBA-16-24 as a highly potent, selective ATR inhibitor for the treatment of FLT3-mutated acute myeloid leukemia. RSC Medicinal Chemistry, 17(4), 2081-2095. https://doi.org/10.1039/d5md01005e

Vancouver

Li P, Ren H, Lan X, Li J, Liu Z, Liu H, et al. Discovery of GBA-16-24 as a highly potent, selective ATR inhibitor for the treatment of FLT3-mutated acute myeloid leukemia. RSC Medicinal Chemistry. 2026;17(4):2081-2095. doi:10.1039/d5md01005e

BibTeX
@article{Li2026,
  author = {Li, Ping and Ren, Haiyan and Lan, Xinyan and Li, Junfei and Liu, Zhi and Liu, Huashuo and Zheng, Zhijie and Zeng, Tianyan and Wang, Peili and Sun, Mingyang and Xu, Lei and Zhang, Yanyan and Zhou, Yubo and Li, Jia and Wang, Mingliang and Jiang, Kailong},
  title = {Discovery of GBA-16-24 as a highly potent, selective ATR inhibitor for the treatment of FLT3-mutated acute myeloid leukemia},
  journal = {RSC Medicinal Chemistry},
  year = {2026},
  volume = {17},
  number = {4},
  pages = {2081--2095},
  doi = {10.1039/d5md01005e}
}
Start for free →